Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells

• Published in: Nature communications Vol. 15; no. 1; pp. 1043 - 14
• Main Authors: Wiendl, Maximilian, Dedden, Mark, Liu, Li-Juan, Schweda, Anna, Paap, Eva-Maria, Ullrich, Karen A.-M., Hartmann, Leonie, Wieser, Luisa, Vitali, Francesco, Atreya, Imke, Müller, Tanja M., Günther, Claudia, Atreya, Raja, Neurath, Markus F., Zundler, Sebastian
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.02.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 13/1; 13/106; 13/21; 13/31; 38/91; 631/250/1619/554; 631/250/249/2510/1402; 631/80/84/2342; 692/4020/1503/257; 82/1; Antibodies; Cell activation; Crohn's disease; Cytotoxicity; E-cadherin; Flow cytometry; Humanities and Social Sciences; Inflammatory bowel disease; Inflammatory bowel diseases; Intestine; Lymphocytes; Lymphocytes T; multidisciplinary; Science; Science (multidisciplinary); Stimulation; Transcriptomics

Despite promising preclinical and earlier clinical data, a recent phase III trial on the anti-β7 integrin antibody etrolizumab in Crohn’s disease (CD) did not reach its primary endpoint. The mechanisms leading to this outcome are not well understood. Here we characterize the β7 + T cell compartment...